JKJúlia Karády

Júlia Karády

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Júlia Karády has a total of 150 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer

    by Giselle Alexandra Suero‐Abreu, Zsofia D. Drobni, Carlos A. Gongora, Jana Taron, Julia Karady, Hannah K. Gilman, Bela Merkely, Hajnalka Vago, Zoltan V. Varga, Ryan J. Sullivan, et al.

    Background: Immune checkpoint inhibitors (ICIs) are associated with a 3‐fold risk of atherosclerotic cardiovascular disease (ASCVD). However, the biology of atherosclerosis is different among women and men, and ASCVD risk factors among women treated with an ICI are incompletely understood. This study aimed to identify factors associated with ASCVD in women following ICIs and to characterize plaque progression. Methods: In a single‐center retrospective study, clinical and cancer‐related factors were compared among women treated with ICIs who did and did not experience ASCVD. Competing risk analysis estimated the effect of ICIs on cardiovascular risk. In an imaging substudy, the rate of atherosclerotic plaque progression post‐treatment was compared between women and men. Results: Among 1188 female patients treated with an ICI, 54 (5%) experienced an ASCVD with a median time to event of 174 days. Patients with ASCVD had a higher prevalence of prior myocardial infarction and coronary revascularization (15% versus 6%, P =0.007) and prior stroke (7% versus 2%, P =0.039). Competing risk analyses, adjusting for cardiovascular risk factors, revealed an almost 3‐fold increased risk of post‐ICI ASCVD in women with prior cardiovascular events (hazard ratio, 2.71 [95% CI, 1.24–5.95]; P =0.013). In an imaging study, the annual rate of plaque progression post‐ICI was 6% for total and 7% for non‐calcified plaque, with similar rates of progression observed in women and men. Conclusions: In female patients treated with ICIs, 5% developed an ASCVD, and a history of cardiovascular events was a risk factor. In an imaging study, plaque progressed in a short time frame after ICI therapy.


  • Risk in Women Emerges at Lower Coronary Plaque Burden Than in Men: PROMISE Trial

    by Jan M. Brendel, Thomas Mayrhofer, Júlia Karády, Márton Kolossváry, Nóra M. Kerkovits, Isabel L. Langenbach, Matthias Jung, Michelle D. Kelsey, Marcel C. Langenbach, Neha Pagidipati, et al.

    BACKGROUND: Quantitative coronary plaque measures differ in prognostic value between women and men. It remains unclear whether cardiovascular risk increases proportionally with plaque extent in both sexes. We aimed to compare cardiovascular risk trajectories across quantitative coronary plaque measures in women and men with stable chest pain. METHODS: We analyzed data from the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) coronary computed tomography angiography arm, quantifying total coronary plaque volume and burden (plaque burden [PB]; % vessel volume), including calcified, noncalcified, and low-attenuation components. Associations with major adverse cardiovascular events (death, myocardial infarction, or unstable angina hospitalization) were assessed using sex-stratified spline Cox models over a median 26 months (interquartile range, 18–34). RESULTS: Among 4267 patients (mean age, 60.4±8.2; 2199 women), plaque was less frequent in women (55% versus 75%; P <0.001), with lower total plaque volume but similar total PB and incident major adverse cardiovascular events (2.3% versus 3.4%). Major adverse cardiovascular event risk became elevated at lower PB in women than in men: for total PB, hazard ratio crossed 1.0 at 20% in women versus 28% in men, reaching hazard ratio 1.5 at 32% in women versus 42% in men, respectively. Noncalcified PB showed a similar pattern, crossing hazard ratio 1.0 at 7% in women versus 9% in men; hazard ratio 1.5 at 13% in women versus 20% in men. Findings were similar after adjustment for atherosclerotic cardiovascular disease risk score. CONCLUSIONS: In women, major adverse cardiovascular events appeared to emerge at a lower PB, and to rise more sharply. Findings support sex-specific interpretation of coronary computed tomography angiography-derived plaque metrics for timely intervention in women. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01174550.


  • Air pollution, coronary artery disease, and cardiovascular events: Insights from the PROMISE trial

    by Marcel C. Langenbach, Thomas Mayrhofer, Isabel L. Langenbach, Michael T. Lu, Julia Karady, David Maintz, Shady Abohashem, Ahmed Tawakol, Neha J. Pagidipati, Svati H. Shah, et al.


  • Open Access

    Lipoprotein subclasses are associated with Hepatic steatosis: insights from the prospective multicenter imaging study for the evaluation of chest pain (PROMISE) clinical trial

    by Julia Karady, Robert W McGarrah, Maggie Nguyen, Stephanie N Giamberardino, Nandini Meyersohn, Michael T Lu, Pedro V Staziaki, Stefan B Puchner, Daniel O Bittner, Borek Foldyna, et al.

  • Open Access

    Polygenic Scores and Preclinical Cardiovascular Disease in Individuals With HIV: Insights From the REPRIEVE Trial

    by Roger S. Zou, Yunfeng Ruan, Buu Truong, Romit Bhattacharya, Michael T. Lu, Júlia Karády, Rachel Bernardo, Phoebe Finneran, Whitney Hornsby, Kathleen V. Fitch, et al.

    Background: Coronary artery disease (CAD) is a leading cause of death among the 38.4 million people with HIV globally. The extent to which cardiovascular polygenic risk scores (PRSs) derived in non‐HIV populations generalize to people with HIV is not well understood. Methods and Results: PRSs for CAD (GPS Mult ) and lipid traits were calculated in a global cohort of people with HIV treated with antiretroviral therapy with low‐to‐moderate atherosclerotic cardiovascular disease risk enrolled in REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV). The PRSs were associated with baseline lipid traits in 4495 genotyped participants, and with subclinical CAD in a subset of 662 who underwent coronary computed tomography angiography. Among participants who underwent coronary computed tomography angiography (mean age, 50.9 [SD, 5.8] years; 16.1% women; 41.8% African, 57.3% European, 1.1% Asian), GPS Mult was associated with plaque presence with odds ratio (OR) per SD in GPS Mult of 1.42 (95% CI, 1.20–1.68; P =3.8×10 −5 ), stenosis >50% (OR, 2.39 [95% CI, 1.48–3.85]; P =3.4×10 −4 ), and noncalcified/vulnerable plaque (OR, 1.45 [95% CI, 1.23–1.72]; P =9.6×10 −6 ). Effects were consistent in subgroups of age, sex, 10‐year atherosclerotic cardiovascular disease risk, ancestry, and CD4 count. Adding GPS Mult to established risk factors increased the C‐statistic for predicting plaque presence from 0.718 to 0.734 ( P =0.02). Furthermore, a PRS for low‐density lipoprotein cholesterol was associated with plaque presence with OR of 1.21 (95% CI, 1.01–1.44; P =0.04), and partially calcified plaque with OR of 1.21 (95% CI, 1.01–1.45; P =0.04) per SD. Conclusions: Among people with HIV treated with antiretroviral therapy without documented atherosclerotic cardiovascular disease and at low‐to‐moderate calculated risk in REPRIEVE, an externally developed CAD PRS was predictive of subclinical atherosclerosis. PRS for low‐density lipoprotein cholesterol was also associated with subclinical atherosclerosis, supporting a role for low‐density lipoprotein cholesterol in HIV‐associated CAD. Registration: URL: https://www.reprievetrial.org ; Unique identifier: NCT02344290.


  • Agreement among high-sensitivity cardiac troponin assays and non-invasive testing, clinical outcomes, and quality-of-care outcomes based on the 2020 European Society of Cardiology Guidelines

    by Júlia Karády, Thomas Mayrhofer, James L Januzzi, James E Udelson, Jerome L Fleg, Bela Merkely, Michael T Lu, William F Peacock, John T Nagurney, Wolfgang Koenig, et al.

    Aims: Quality-of-care and safety of patients with suspected acute coronary syndrome (ACS) would benefit if management was independent of which high-sensitivity cardiac troponin (hs-cTn) assay was used for risk stratification. We aimed to determine the concordance of hs-cTn assays to risk-stratify patients with suspected ACS according to the European Society of Cardiology (ESC) 2020 Guidelines. Methods and results: Blood samples were obtained at arrival and at 2 h from patients with suspected ACS using four hs-cTn assays. The patients were classified into rule-out/observe/rule-in strata based on the ESC 2020 Guidelines. Concordance was determined among the assays for rule-out/observe/rule-in strata. The prevalences of significant underlying disease (≥50% stenosis on coronary computed tomography or inducible myocardial ischaemia on stress testing) and adjudicated ACS, plus quality-of-care outcomes, were compared. Among 238 patients (52.7 ± 8.0 years; 40.3% female), the overall concordance across assays to classify patients into rule-out/observe/rule-in strata was 74.0% (176/238). Platforms significantly differed for rule-out (89.9 vs. 76.5 vs. 78.6 vs. 86.6%, P < 0.001) and observe strata (6.7 vs. 20.6 vs. 17.7 vs. 9.2%, P < 0.001), but not for rule-in strata (3.4 vs. 2.9 vs. 3.8 vs. 4.2%, P = 0.62). Among patients in ruled-out strata, 19.1–21.6% had significant underlying disease and 3.3–4.2% had ACS. The predicted disposition of patients and cost-of-care differed across the assays (all P < 0.001). When compared with observed strata, conventional troponin-based management and predicted quality-of-care outcomes significantly improved with hs-cTn-based strategies (direct discharge: 21.0 vs. 80.3–90.8%; cost-of-care: $3889 ± 4833 vs. $2578 ± 2896–2894 ± 4371, all P < 0.001). Conclusion: Among individuals with suspected ACS, patient management may differ depending on which hs-cTn assay is utilized. More data are needed regarding the implications of inter-assay differences. Trail registration: NCT01084239.


  • Open Access

    Branched‐Chain Amino Acids in Computed Tomography–Defined Adipose Depots and Coronary Artery Disease: A PROMISE Trial Biomarker Substudy

    by Elizabeth Zhao, Stephanie N. Giamberardino, Neha J. Pagidipati, Deepak Voora, Geoffrey S. Ginsburg, Udo Hoffmann, Júlia Karády, Maros Ferencik, Pamela S. Douglas, Borek Foldyna, et al.

    Background: The interplay between branched‐chain amino acid (BCAA) metabolism, an important pathway in adiposity and cardiometabolic disease, and visceral adipose depots such as hepatic steatosis (HS) and epicardial adipose tissue is unknown. We leveraged the PROMISE clinical trial with centrally adjudicated coronary computed tomography angiography imaging to determine relationships between adipose depots, BCAA dysregulation, and coronary artery disease (CAD). Methods and Results: The PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) trial randomized 10 003 outpatients with stable chest pain to computed tomography angiography versus standard‐of‐care diagnostics. For this study, we included 1798 participants with available computed tomography angiography data and biospecimens. Linear and logistic regression were used to determine associations between a molar sum of BCAAs measured by nuclear magnetic resonance spectroscopy with body mass index, adipose traits, and obstructive CAD. Mendelian randomization was then used to determine if BCAAs are in the causal pathway for adipose depots or CAD. The study sample had a mean age of 60 years (SD, 8.0), body mass index of 30.6 (SD, 5.9), and epicardial adipose tissue volume of 57.3 (SD, 21.3) cm 3 /m 2 ; 27% had HS, and 14% had obstructive CAD. BCAAs were associated with body mass index (multivariable beta 0.12 per SD increase in BCAA [95% CI, 0.08–0.17]; P =4×10 −8 ). BCAAs were also associated with HS (multivariable odds ratio [OR], 1.46 per SD increase in BCAAs [95% CI, 1.28–1.67]; P =2×10 −8 ), but BCAAs were associated only with epicardial adipose tissue volume (odds ratio, 1.18 [95% CI, 1.07–1.32]; P =0.002) and obstructive CAD (OR, 1.18 [95% CI, 1.04–1.34]; P =0.009) in univariable models. Two‐sample Mendelian randomization did not support the role of BCAAs as within the causal pathways for HS or CAD. Conclusions: BCAAs have been implicated in the pathogenesis of cardiometabolic diseases, and adipose depots have been associated with the risk of CAD. Leveraging a large clinical trial, we further establish the role of dysregulated BCAA catabolism in HS and CAD, although BCAAs did not appear to be in the causal pathway of either disease. This suggests that BCAAs may serve as an independent circulating biomarker of HS and CAD but that their association with these cardiometabolic diseases is mediated through other pathways.


  • IMMUNE CHECKPOINT INHIBITORS AND PROGRESSION OF ATHEROSCLEROSIS AMONG PATIENTS WITH LUNG CANCER

    by Zsofia Drobni, Jana Taron, Carlos A. Gongora, Giselle A. Suero-Abreu, Julia Karady, Nicholas James Leeper, Hannah Gilman, Supraja Sama, Bela Merkely, Pal Maurovich-Horvat, et al.